Efficacy of combination therapy (Sofosbuvir, Pegylated interferon and Ribavirin) in treatment of chronic hepatitis C in Egyptian patients

Abstract

Hepatitis C is worldwide problem and endemic disease in Egypt that has a lot of resounding health and economic burden. The availability of the newer agents (DAAs) has become a new hope for a lot of patients who cannot tolerate the older treatment with interferon and ribavirin for 48 weeks. These drugs are also powerful tools in the physician arsenal to deal with the problem of HCV; however these drugs are far from being evaluated and studied completely. Our study which was conducted in the national hepatology and tropical medicine research institute (NHTMRI) on 100 Egyptian patients who were eligible to be treated with Sofosbuvir, Interferon and ribavirin. The treatment protocol was the Recommended regimen for treatment of patients with HCV genotype 4; Daily sofosbuvir (400 mg) and weight-based RBV (1000 mg [<75 kg] to 1200 mg [≥75 kg]) plus weekly PEG for 12 weeks is recommended for IFN-eligible persons. Daily sofosbuvir (400 mg) plus weight-based RBV (1000 mg [<75 kg] to 1200 mg [≥75 kg]) for 24 weeks is recommended for IFN-ineligible patients. Our study showed that the overall sustained virological response (SVR) was 76 %. There was no statistically significant correlation between the possibility of achieving SVR and Age, sex, Diabetes mellitus, smoking, viral load before treatment, grade of fibrosis and early negative response in the course of treatment.

999